


EGFR-IN-74

Cat. No.:	HY-151981
Molecular Formula:	C ₃₂ H ₂₈ BrF ₃ N ₆ O ₄ S
Molecular Weight:	729.57
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EGFR-IN-74 (Compound 21) is a potent EGFR inhibitor with an IC ₅₀ of 138 nM against EGFR L858R/T790M. EGFR-IN-74 induces cancer cell apoptosis ^[1] .																
IC₅₀ & Target	EGFR ^{L858R/T790M} 138 nM (IC ₅₀)																
In Vitro	<p>EGFR-IN-74 (Compound 21) (72 h) shows anticancer activity against cells harbouring a different status of the EGFR^[1]. EGFR-IN-74 (0.01 μM; 24 and 48 h) induces apoptosis in cancer cells^[1]. EGFR-IN-74 forms a stable complex with the EGFR enzyme without much structural rearrangement^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCC827 (EGFR Del E746-A750), NCI-H1975 (EGFR L858R/T790 M), A549 (WT EGFR), A549 and BEAS-2B cells</td> </tr> <tr> <td>Concentration:</td> <td></td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability with IC₅₀s of 0.010 ± 0.02, 0.21 ± 0.99, 0.99 ± 0.11, 2.99 ± 0.21 and 85.14 ± 0.12 μM against HCC827 (EGFR Del E746-A750), NCI-H1975 (EGFR L858R/T790 M), A549 (WT EGFR), A549 and BEAS-2B cells respectively.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCC827 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.10 and 1.00 μM</td> </tr> <tr> <td>Incubation Time:</td> <td></td> </tr> <tr> <td>Result:</td> <td>Showed an ability to phosphorylate AKT.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p>	Cell Line:	HCC827 (EGFR Del E746-A750), NCI-H1975 (EGFR L858R/T790 M), A549 (WT EGFR), A549 and BEAS-2B cells	Concentration:		Incubation Time:	72 h	Result:	Inhibited cell viability with IC ₅₀ s of 0.010 ± 0.02, 0.21 ± 0.99, 0.99 ± 0.11, 2.99 ± 0.21 and 85.14 ± 0.12 μM against HCC827 (EGFR Del E746-A750), NCI-H1975 (EGFR L858R/T790 M), A549 (WT EGFR), A549 and BEAS-2B cells respectively.	Cell Line:	HCC827 cells	Concentration:	0.01, 0.10 and 1.00 μM	Incubation Time:		Result:	Showed an ability to phosphorylate AKT.
Cell Line:	HCC827 (EGFR Del E746-A750), NCI-H1975 (EGFR L858R/T790 M), A549 (WT EGFR), A549 and BEAS-2B cells																
Concentration:																	
Incubation Time:	72 h																
Result:	Inhibited cell viability with IC ₅₀ s of 0.010 ± 0.02, 0.21 ± 0.99, 0.99 ± 0.11, 2.99 ± 0.21 and 85.14 ± 0.12 μM against HCC827 (EGFR Del E746-A750), NCI-H1975 (EGFR L858R/T790 M), A549 (WT EGFR), A549 and BEAS-2B cells respectively.																
Cell Line:	HCC827 cells																
Concentration:	0.01, 0.10 and 1.00 μM																
Incubation Time:																	
Result:	Showed an ability to phosphorylate AKT.																

Cell Line:	HCC827 cells
Concentration:	0.010 μ M (IC ₅₀ value)
Incubation Time:	24 and 48 h
Result:	Induced early apoptosis and late apoptosis of 26.8% and 4.2% respectively, in comparison with control, with early apoptosis of 2.1% and late apoptosis of 1.1%.

REFERENCES

[1]. Kardile RA, et al. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114889.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA